• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-1 阻断型癌症免疫疗法中的免疫代谢。

Immune metabolism in PD-1 blockade-based cancer immunotherapy.

机构信息

Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Yoshida, Konoe-cho, Sakyo-ku, Kyoto, Japan.

出版信息

Int Immunol. 2021 Jan 1;33(1):17-26. doi: 10.1093/intimm/dxaa046.

DOI:10.1093/intimm/dxaa046
PMID:32622347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7771015/
Abstract

Energy metabolism plays an important role in proliferating cells. Recent reports indicate that metabolic regulation or metabolic products can control immune cell differentiation, fate and reactions. Cancer immunotherapy based on blockade of programmed cell death protein 1 (PD-1) has been used worldwide, but a significant fraction of patients remain unresponsive. Therefore, clarifying the mechanisms and overcoming the unresponsiveness are urgent issues. Because cancer immunity consists of interactions between the cancer and host immune cells, there has recently been a focus on the metabolic interactions and/or competition between the tumor and the immune system to address these issues. Cancer cells render their microenvironment immunosuppressive, driving T-cell dysfunction or exhaustion, which is advantageous for cancer cell survival. However, accumulating mechanistic evidence of T-cell and cancer cell metabolism has gradually revealed that controlling the metabolic pathways of either type of cell can overcome T-cell dysfunction and reprogram the metabolic balance in the tumor microenvironment. Here, we summarize the role of immune metabolism in T-cell-based immune surveillance and cancer immune escape. This new concept has boosted the development of combination therapy and predictive biomarkers in cancer immunotherapy with immune checkpoint inhibitors.

摘要

能量代谢在增殖细胞中起着重要作用。最近的报告表明,代谢调控或代谢产物可以控制免疫细胞的分化、命运和反应。基于程序性细胞死亡蛋白 1(PD-1)阻断的癌症免疫疗法已在全球范围内应用,但仍有相当一部分患者无反应。因此,阐明机制和克服无反应性是当务之急。由于癌症免疫由癌症和宿主免疫细胞之间的相互作用组成,最近人们关注肿瘤和免疫系统之间的代谢相互作用和/或竞争,以解决这些问题。癌细胞使它们的微环境免疫抑制,导致 T 细胞功能障碍或衰竭,这有利于癌细胞的存活。然而,越来越多的 T 细胞和癌细胞代谢的机制证据逐渐揭示,控制任何一种细胞的代谢途径都可以克服 T 细胞功能障碍,并重新编程肿瘤微环境中的代谢平衡。在这里,我们总结了免疫代谢在基于 T 细胞的免疫监视和癌症免疫逃逸中的作用。这一新概念促进了癌症免疫疗法中免疫检查点抑制剂联合治疗和预测生物标志物的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/fd2ebda27f0a/dxaa046_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/ebb27f875f5d/dxaa046_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/1ad51e045a74/dxaa046_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/2158a14b1143/dxaa046_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/fd2ebda27f0a/dxaa046_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/ebb27f875f5d/dxaa046_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/1ad51e045a74/dxaa046_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/2158a14b1143/dxaa046_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4726/7771015/fd2ebda27f0a/dxaa046_fig4.jpg

相似文献

1
Immune metabolism in PD-1 blockade-based cancer immunotherapy.PD-1 阻断型癌症免疫疗法中的免疫代谢。
Int Immunol. 2021 Jan 1;33(1):17-26. doi: 10.1093/intimm/dxaa046.
2
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.肿瘤细胞降低 T 细胞中的线粒体活性,从而逃避 PD-1 阻断疗法。
Elife. 2020 Mar 3;9:e52330. doi: 10.7554/eLife.52330.
3
Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.联合治疗策略提高 PD-1 阻断疗效:癌症免疫治疗的新时代。
J Intern Med. 2018 Feb;283(2):110-120. doi: 10.1111/joim.12708. Epub 2017 Nov 16.
4
Regulation of PD-1 in T cells for cancer immunotherapy.T 细胞中 PD-1 的调控用于癌症免疫治疗。
Eur J Pharmacol. 2020 Aug 15;881:173240. doi: 10.1016/j.ejphar.2020.173240. Epub 2020 Jun 1.
5
Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.癌症免疫疗法中的免疫检查点阻断:PD-1/PD-L1 抑制剂的作用机制、临床疗效和安全性特征。
Arch Immunol Ther Exp (Warsz). 2020 Nov 13;68(6):36. doi: 10.1007/s00005-020-00601-6.
6
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.癌症治疗中的PD-1/PD-L1阻断:观点与问题
Int J Clin Oncol. 2016 Jun;21(3):462-73. doi: 10.1007/s10147-016-0959-z. Epub 2016 Feb 22.
7
Immunotherapy and predictive immunologic profile: the tip of the iceberg.免疫治疗和预测性免疫特征:冰山一角。
Med Oncol. 2021 Mar 31;38(5):51. doi: 10.1007/s12032-021-01497-8.
8
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?PD-1 抑制剂治疗后免疫微环境会发生什么变化?
Front Immunol. 2021 Dec 23;12:773168. doi: 10.3389/fimmu.2021.773168. eCollection 2021.
9
Prognostic Biomarkers for Melanoma Immunotherapy.黑色素瘤免疫治疗的预后生物标志物
Curr Oncol Rep. 2020 Feb 11;22(3):25. doi: 10.1007/s11912-020-0886-z.
10
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.PD-1 和 PD-L1 在癌症免疫治疗中的作用:临床意义和未来思考。
Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19.

引用本文的文献

1
Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades.克服PD-1/PD-L1阻断耐药的策略:聚焦于与免疫检查点阻断剂联合使用
J Cancer. 2025 Jul 24;16(11):3425-3449. doi: 10.7150/jca.108163. eCollection 2025.
2
Adoptive T-Cell Therapy in Sarcomas.肉瘤的过继性T细胞疗法
Curr Oncol Rep. 2025 Aug 14. doi: 10.1007/s11912-025-01706-x.
3
Mitochondrial Metabolism in T-Cell Exhaustion.T细胞耗竭中的线粒体代谢

本文引用的文献

1
ACC1 determines memory potential of individual CD4 T cells by regulating de novo fatty acid biosynthesis.ACC1 通过调节从头脂肪酸生物合成来决定个体 CD4 T 细胞的记忆潜能。
Nat Metab. 2019 Feb;1(2):261-275. doi: 10.1038/s42255-018-0025-4. Epub 2019 Jan 14.
2
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy.抗PD-1/PD-L1治疗中基于外周血免疫细胞的生物标志物
Immune Netw. 2020 Feb 10;20(1):e8. doi: 10.4110/in.2020.20.e8. eCollection 2020 Feb.
3
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Int J Mol Sci. 2025 Jul 31;26(15):7400. doi: 10.3390/ijms26157400.
4
Spatiotemporal Heterogeneity of Tumor Glucose Metabolism Reprogramming: From Single-Cell Mechanisms to Precision Interventions.肿瘤葡萄糖代谢重编程的时空异质性:从单细胞机制到精准干预
Int J Mol Sci. 2025 Jul 18;26(14):6901. doi: 10.3390/ijms26146901.
5
Genital herpes shedding episodes associate with alterations in the spatial organization and activation of mucosal immune cells.生殖器疱疹排毒发作与黏膜免疫细胞的空间组织和激活改变有关。
bioRxiv. 2025 Jun 27:2025.06.24.661157. doi: 10.1101/2025.06.24.661157.
6
Immunometabolism signature derived from on-treatment tumor specimens predicts immune checkpoint blockade response in metastatic melanoma.从治疗中的肿瘤标本得出的免疫代谢特征可预测转移性黑色素瘤对免疫检查点阻断的反应。
Discov Oncol. 2025 Jul 1;16(1):1230. doi: 10.1007/s12672-025-02428-z.
7
PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review).PI3K/AKT/mTOR和PD-1/CTLA-4/CD28信号通路作为癌症免疫治疗的关键靶点(综述)
Oncol Lett. 2024 Sep 26;28(6):567. doi: 10.3892/ol.2024.14700. eCollection 2024 Dec.
8
The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance.肌肉减少症对非小细胞肺癌中PD-1抑制剂疗效的影响及克服耐药性的潜在策略。
Front Pharmacol. 2024 Jul 19;15:1377666. doi: 10.3389/fphar.2024.1377666. eCollection 2024.
9
Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer.非小细胞肺癌患者新辅助PD-1阻断早期反应的血液分子和细胞生物标志物
Cancer Cell Int. 2024 Jun 29;24(1):225. doi: 10.1186/s12935-024-03412-3.
10
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy.用于预测肿瘤免疫检查点抑制剂疗效的生物标志物和计算模型。
Front Immunol. 2024 Mar 8;15:1368749. doi: 10.3389/fimmu.2024.1368749. eCollection 2024.
肿瘤细胞降低 T 细胞中的线粒体活性,从而逃避 PD-1 阻断疗法。
Elife. 2020 Mar 3;9:e52330. doi: 10.7554/eLife.52330.
4
Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity.代谢调控 Treg 细胞稳定性、可塑性和组织特异性异质性。
Front Immunol. 2019 Dec 11;10:2716. doi: 10.3389/fimmu.2019.02716. eCollection 2019.
5
Current issues and perspectives in PD-1 blockade cancer immunotherapy.PD-1 阻断癌症免疫疗法的当前问题和展望。
Int J Clin Oncol. 2020 May;25(5):790-800. doi: 10.1007/s10147-019-01588-7. Epub 2020 Jan 3.
6
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.宿主免疫代谢生物标志物联合用于 PD-1 阻断癌症免疫治疗。
JCI Insight. 2020 Jan 30;5(2):133501. doi: 10.1172/jci.insight.133501.
7
The clock is ticking: the impact of ageing on T cell metabolism.时间紧迫:衰老对T细胞代谢的影响。
Clin Transl Immunology. 2019 Nov 18;8(11):e01091. doi: 10.1002/cti2.1091. eCollection 2019.
8
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?癌症免疫治疗中的外周免疫相关生物标志物:我们能否实现其预测潜能?
J Immunother Cancer. 2019 Nov 27;7(1):325. doi: 10.1186/s40425-019-0799-2.
9
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.谷氨酰胺阻断诱导了不同的代谢程序来克服肿瘤免疫逃逸。
Science. 2019 Nov 22;366(6468):1013-1021. doi: 10.1126/science.aav2588. Epub 2019 Nov 7.
10
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.除 PD-1、PD-L1 和 CTLA-4 以外的抑制性受体和配体:突破还是备份。
Nat Immunol. 2019 Nov;20(11):1425-1434. doi: 10.1038/s41590-019-0512-0. Epub 2019 Oct 14.